(Q71261799)
Statements
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer (English)
B L Gause
M Sznol
W C Kopp
J E Janik
J W Smith
R G Steis
W J Urba
W Sharfman
R G Fenton
S P Creekmore
J Holmlund
K C Conlon
L A VanderMolen